Tresiba and GLP-1 combination therapy While Tresiba is not a GLP-1, the two drug classes are frequently prescribed together
Keep an eye on symptoms during the lower dose phase
Isaacson SH, Ondo W, Jackson CE, Trosch RM, Molho E, Pagan F, et al
However, while statin therapy mitigates systemic ASCVD risk, silent vascular progression particularly lower-extremity peripheral artery disease (PAD) frequently goes undetected in primary care until patients present with claudication or worse
Treatment strategies organized by reaction type Different reactions require different approaches
If, however, Mike flat out recommended the peptide by saying something like, I think you should take this, I would find that ethically dubious